Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Taltz Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2013-A

    Specialty Guideline Management Taltz

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2013-A alerts

    Get alerted when Policy 2013-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continuation coverage for Taltz (ixekizumab) used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It applies to members seeking initial or renewal authorization and establishes clinical criteria, documentation, prescriber specialty, and safety requirements.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Taltz
    Policy CodePolicy 2013-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the information required to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4FDA-approved indications addressed
    12 monthsStandard authorization period
    Age 6+Minimum age for plaque psoriasis coverage
    10% BSAPlaque psoriasis body-surface-area threshold
    2 NSAIDs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum NSAID trials for an ankylosing spondylitis or nr-axSpA pathway
    12Clinical and product references cited

    Coverage Criteria

    Initial therapy: plaque psoriasis

    Covered for members age 6 years or older when any of the following pathways is met.

    Plaque psoriasis initial therapy

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    • Disease severity and treatment pathway

      • Crucial body areas are affected.Hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas
      • Extensive involvement: At least 10% of BSA is affected.>= 10% BSA
      • Limited BSA with treatment issue

        • Treatment failure, intolerance, or avoidance: The member has an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.

    Initial therapy: psoriatic arthritis

    Covered for adult members when any of the following pathways is met.

    Psoriatic arthritis initial therapy

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    • Mild to moderate disease pathway

      • Mild to moderate qualifying criterion: The member has an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug at an adequate dose and duration; has an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug; or has enthesitis or predominantly axial disease.
    • Severe disease: Member has severe disease.Severe disease

    Initial therapy: ankylosing spondylitis and nr-axSpA

    Covered for adult members when any of the following pathways is met.

    AS or nr-axSpA initial therapy

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.
    • NSAID inadequate response: Member has had an inadequate response to at least two NSAIDs.At least 2 NSAIDs
    • NSAID intolerance or contraindication: Member has intolerance or contraindication to two or more NSAIDs.At least 2 NSAIDs

    Continuation therapy: plaque psoriasis

    Covered for members age 6 years or older who are using Taltz for moderate to severe plaque psoriasis and achieve or maintain a positive clinical response.

    Plaque psoriasis continuation response

    • BSA response: Reduction in BSA affected from baseline.Reduction from baseline
    • Signs and symptoms response: Improvement in signs and symptoms from baseline.Improvement from baseline

    Continuation therapy: psoriatic arthritis

    Covered for adult members using Taltz for psoriatic arthritis who achieve or maintain a positive clinical response.

    Psoriatic arthritis continuation response

    • Clinical response: Improvement in any of the specified psoriatic arthritis measures from baseline.Improvement from baseline in >= 1 measure

    Continuation therapy: ankylosing spondylitis and nr-axSpA

    Covered for adult members using Taltz for ankylosing spondylitis or non-radiographic axial spondyloarthritis who achieve or maintain a positive clinical response.

    AS or nr-axSpA continuation response

    • Clinical response: Improvement in any of the specified ankylosing spondylitis or nr-axSpA measures from baseline.Improvement from baseline in >= 1 measure

    Taltz must not be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Indications other than the listed FDA-approved uses are considered experimental, investigational, and not medically necessary.

    Coverage applies to moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for systemic therapy or phototherapy; active psoriatic arthritis in adults; active ankylosing spondylitis in adults; and active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation.

    Initial Therapy Criteria

    Plaque psoriasis initial therapy — 12-month authorization

    Authorization of 12 months may be granted for members age 6 years or older when any of the following pathways is met.

    Plaque psoriasis initial criteria

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.
    • Disease severity and treatment pathway

      • Crucial body areas are affected.Hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas
      • Extensive involvement: At least 10% of BSA is affected.

    Continuation Therapy Criteria

    Plaque psoriasis continuation — 12-month authorization

    Authorization of 12 months may be granted for eligible members age 6 years or older, including new members, who achieve or maintain a positive clinical response.

    Plaque psoriasis response

    • BSA response: Reduction in BSA affected from baseline.Reduction from baseline
    • Signs and symptoms response: Improvement in signs and symptoms from baseline.Improvement from baseline

    Psoriatic arthritis continuation — 12-month authorization

    Authorization of 12 months may be granted for eligible adult members, including new members, who achieve or maintain a positive clinical response.

    Prior Therapy Requirements

    ConditionPrior therapy requirementException to prior therapy
    Plaque psoriasisMember must previously have received a biologic or targeted synthetic drug indicated for moderate to severe plaque psoriasis, such as Sotyktu or Otezla.The disease-severity pathway is met: crucial body-area involvement; at least 10% BSA involvement; or at least 3% BSA involvement plus inadequate response or intolerance to phototherapy, methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
    ConditionPrior therapy requirementException to prior therapy
    Psoriatic arthritisMember must previously have received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.The alternative disease pathway is met: mild to moderate disease with inadequate response, intolerance, or contraindication to methotrexate, leflunomide, or another conventional synthetic drug, or enthesitis or predominantly axial disease; or severe disease.
    ConditionPrior therapy requirementException to prior therapy
    Ankylosing spondylitis or non-radiographic axial spondyloarthritisMember must previously have received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.The NSAID pathway is met: inadequate response to at least two NSAIDs, or intolerance or contraindication to two or more NSAIDs.

    Clinical Thresholds and Treatment History

    Plaque psoriasis body surface area
    Extensive involvement thresholdAt least 10% of body surface area (BSA) is affected.
    Limited involvement thresholdAt least 3% of BSA is affected.
    Additional requirement at 3% BSAAn inadequate response or intolerance to phototherapy, methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid methotrexate, cyclosporine, and acitretin, must also be documented.
    Plaque psoriasis crucial body areas
    Hands and feetCrucial body areas include the hands and feet.
    Face and neckCrucial body areas include the face and neck.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Period

    Initial authorization may be granted for 12 months when the applicable indication-specific coverage criteria are met for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.

    Prior Authorization

    Continuation Authorization Period

    Continuation authorization may be granted for 12 months when the member achieves or maintains a positive clinical response, demonstrated by improvement or maintenance of relevant disease measures and signs or symptoms.

    Prior Authorization

    Required Prescriber Specialty

    The requested medication must be prescribed by or in consultation with the required specialist for the indication.

    • Plaque psoriasis: dermatologist

    Policy Background

    Taltz (ixekizumab) is used under this policy for inflammatory dermatologic and rheumatologic diseases, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

    Definitions

    Plaque psoriasis (PsO)
    ConditionModerate to severe plaque psoriasis.
    Treatment eligibilityPatients are candidates for systemic therapy or phototherapy.
    Policy populationThe indication applies to patients 6 years of age and older.
    Non-radiographic axial spondyloarthritis (nr-axSpA)
    ConditionNon-radiographic axial spondyloarthritis (nr-axSpA).
    Disease statusThe condition must be active.
    Objective findingThere must be objective signs of inflammation.
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Taltz
    Policy CodePolicy 2013-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the information required to initiate prior authorization review.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaPrior Therapy RequirementsClinical Thresholds and Treatment HistoryAuthorization and Documentation RequirementsPolicy BackgroundDefinitions
    >= 10% BSA
  1. Limited BSA with treatment issue

    • Treatment failure, intolerance, or avoidance: The member has an inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.
  2. Psoriatic arthritis initial therapy — 12-month authorization

    Authorization of 12 months may be granted for adult members with active psoriatic arthritis when any of the following pathways is met.

    Psoriatic arthritis initial criteria

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis, such as Rinvoq or Otezla.
    • Mild to moderate disease pathway

      • Mild to moderate qualifying criterion: The member has an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug at an adequate dose and duration; has an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug; or has enthesitis or predominantly axial disease.
    • Severe disease: Member has severe disease.Severe disease

    AS or nr-axSpA initial therapy — 12-month authorization

    Authorization of 12 months may be granted for adult members with active ankylosing spondylitis or active non-radiographic axial spondyloarthritis when any of the following pathways is met.

    AS or nr-axSpA initial criteria

    • Prior advanced therapy: Member has previously received a biologic or targeted synthetic drug indicated for active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, such as Rinvoq or Xeljanz.
    • NSAID inadequate response: Member has had an inadequate response to at least two NSAIDs.At least 2 NSAIDs
    • NSAID intolerance or contraindication: Member has intolerance or contraindication to two or more NSAIDs.At least 2 NSAIDs

    Psoriatic arthritis response

    • Clinical response: Improvement from baseline in at least one of swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or CRP.Improvement from baseline in >= 1 measure

    AS or nr-axSpA continuation — 12-month authorization

    Authorization of 12 months may be granted for eligible adult members, including new members, who achieve or maintain a positive clinical response.

    AS or nr-axSpA response

    • Clinical response: Improvement from baseline in at least one of functional status, total spinal pain, inflammation such as morning stiffness, swollen joints, tender joints, or CRP.Improvement from baseline in >= 1 measure
    Scalp
    The scalp is a crucial body area.
    Genitals and groinThe genitals and groin are crucial body areas.
    Intertriginous areasIntertriginous areas are crucial body areas.
    NSAID treatment history
    Inadequate responseInadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs).
    IntoleranceIntolerance to two or more NSAIDs.
    ContraindicationContraindication to two or more NSAIDs.
  3. Psoriatic arthritis: rheumatologist or dermatologist
  4. Ankylosing spondylitis or non-radiographic axial spondyloarthritis: rheumatologist
  5. Denial Risk

    Safety and Concomitant Therapy Requirements

    Before initiation, the member must be evaluated for tuberculosis infection. Taltz cannot be used concomitantly with another biologic or targeted synthetic drug for the same indication.

    • Document tuberculosis evaluation before biologic or targeted synthetic therapy.
    • Do not combine Taltz with another biologic or targeted synthetic drug for the same indication.
    Billing Rule

    Dosing Limits

    Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

    Billing Rule

    Authoritative Dosing Requirements

    Approval may be subject to authoritative dosing limits, including limits established by FDA-approved labeling, accepted compendia, or evidence-based practice guidelines.

    Step Therapy

    Plaque Psoriasis Prior Therapy

    For moderate to severe plaque psoriasis, document that the member is 6 years of age or older and has previously received a biologic or targeted synthetic drug indicated for plaque psoriasis, such as Sotyktu or Otezla.

    • If prior therapy is not advisable, submit the clinical reason to avoid it.
    • Initial plaque psoriasis criteria may also require affected crucial body areas, at least 10% BSA, or at least 3% BSA with inadequate response, intolerance, or a clinical reason to avoid phototherapy or methotrexate, cyclosporine, and acitretin.
    Step Therapy

    Psoriatic Arthritis Prior Therapy

    For active psoriatic arthritis, document that the adult member has previously received a biologic or targeted synthetic drug indicated for psoriatic arthritis, such as Rinvoq or Otezla.

    • If prior therapy is not advisable, submit the clinical reason to avoid it.
    • Coverage may also be supported by inadequate response to, or intolerance or contraindication to, conventional synthetic therapy; enthesitis or predominantly axial disease; or severe disease.
    Step Therapy

    Axial Spondyloarthritis Prior Therapy

    For active ankylosing spondylitis or active non-radiographic axial spondyloarthritis, document that the adult member has previously received a biologic or targeted synthetic drug indicated for the condition, such as Rinvoq or Xeljanz.

    • If prior therapy is not advisable, submit the clinical reason to avoid it.
    • Coverage may also be supported by inadequate response to at least two NSAIDs or intolerance or contraindication to two or more NSAIDs.
    Prior Authorization

    Prior Authorization Submission

    Submit the information necessary to initiate prior authorization review for Taltz.

    • Provide the applicable clinical documentation, medical records, chart notes, claims history, and treatment history described below.
    Documentation Required

    Initial Plaque Psoriasis Documentation

    For an initial plaque psoriasis request, submit documentation of the affected area or areas and body surface area affected, when applicable, along with treatment history and response.

    • Chart notes or medical record documentation of affected areas and BSA.
    • Documentation or claims history of previous medications tried and response to therapy.
    • Clinical reason to avoid a therapy when treatment is not advisable.
    Documentation Required

    Continuation Plaque Psoriasis Documentation

    For continuation plaque psoriasis requests, submit documentation showing decreased BSA affected and/or improvement in signs and symptoms.

    • Document reduction in BSA from baseline.
    • Document improvement in itching, redness, flaking, scaling, burning, cracking, pain, or other relevant signs and symptoms.
    Documentation Required

    Initial Inflammatory Arthritis Documentation

    For an initial inflammatory arthritis request, submit chart notes, medical records, or claims history supporting previous medications tried and the member’s clinical status.

    • Applies to psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
    • Include response to prior therapy or the clinical reason therapy is not advisable.
    • Include disease-specific documentation supporting the applicable initial coverage criteria.
    Documentation Required

    Continuation Inflammatory Arthritis Documentation

    For continuation inflammatory arthritis requests, submit chart notes or medical records documenting ongoing use and a positive clinical response.

    • Applies to psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
    • Document improvement or maintenance of relevant disease measures, signs, or symptoms from baseline.
    Denial Risk

    Unapproved or Non-Compendial Indication

    Requests for indications outside the covered FDA-approved indications are considered experimental or investigational and are not medically necessary.

    • Covered indications include moderate to severe plaque psoriasis in members 6 years of age and older who are candidates for systemic therapy or phototherapy.
    • Covered adult indications include active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.
    Denial Risk

    Pretreatment Tuberculosis Evaluation Required

    Coverage may be denied when the member has not been evaluated for tuberculosis infection before initiation of a biologic or targeted synthetic drug associated with increased TB risk.

    • Submit documentation of the pretreatment TB evaluation when requested.
    Denial Risk

    No Concomitant Same-Indication Therapy

    Taltz cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Confirm that no other biologic or targeted synthetic therapy is being used for the same condition.
    Prior Authorization

    Initial Clinical Criteria Required

    Initial authorization requires the applicable prior therapy history or disease-specific clinical criteria for the requested indication.

    • Plaque psoriasis: prior biologic or targeted synthetic therapy, or applicable BSA, crucial-area, phototherapy, or conventional pharmacologic criteria.
    • Psoriatic arthritis: prior biologic or targeted synthetic therapy, or applicable conventional synthetic therapy, enthesitis or predominantly axial disease, or severe disease criteria.
    • Ankylosing spondylitis or non-radiographic axial spondyloarthritis: prior biologic or targeted synthetic therapy, or inadequate response to or intolerance or contraindication to the required NSAID trials.
    Prior Authorization

    Positive Response Required for Continuation

    Continuation authorization requires documented improvement or maintenance of relevant disease measures and signs or symptoms from baseline.

    • Plaque psoriasis: reduced BSA or improved signs and symptoms.
    • Psoriatic arthritis: improvement in swollen or tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or CRP.
    • Ankylosing spondylitis or non-radiographic axial spondyloarthritis: improvement in functional status, spinal pain, inflammation, swollen or tender joints, or CRP.
    BSA
    AbbreviationBSA means body surface area.
    Clinical meaningBSA is the body surface area affected by plaque psoriasis.
    Use in coverage criteriaAffected BSA is used to assess plaque psoriasis severity, including thresholds of at least 10% or at least 3% with an additional qualifying criterion.